Both in Pharmaceuticals
Evolus vs CytomX Therapeutics
Over the past year EOLS returned +15.3% and CTMX returned −44.5%; their daily moves had a correlation of 0.26.
EOLS +15.3% CTMX −44.5%Growth of $1, one year, split-adjusted
| Metric | EOLS | CTMX |
|---|---|---|
| Price | $7.37 | $2.18 |
| Market cap | $486.8M | $475.0M |
| Today | +2.93% | −2.24% |
| 1 month | −1.3% | −15.5% |
| 6 months | +15.7% | −46.6% |
| Year to date | +10.8% | −48.8% |
| 1 year | +14.1% | −38.9% |
| Revenue growth (YoY) | +21.2% | −92.4% |
| Gross margin | 68.0% | 100.0% |
| Net margin | −9.6% | −1457.4% |
| P/E (TTM) | — | — |
| Price / sales | 1.5× | 26.0× |
| Net cash | -$141.9M | $330.3M |
| Dividend yield | — | — |
| Volatility (60d) | 52.8% | 67.6% |
| Short % of float | 12.2% | 21.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).